Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.

Science advances·2026
Same author

The Use of Deep Learning in RNA Therapeutic Development.

ACS nano·2026
Same author

Wireless battery-free oxygenation devices enable extended immunosuppression-free islet transplantation in minimally invasive sites.

Device·2026
Same author

The long noncoding RNA <i>lnc-FAM164A1</i>-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approach.

Frontiers in immunology·2026
Same author

Tuning the immune response to mRNA vaccines.

Nature biotechnology·2026
Same author

Therapeutic Spp1 silencing in TREM2<sup>+</sup> cardiac macrophages suppresses atrial fibrillation.

Nature cardiovascular research·2026

Related Experiment Video

Updated: May 23, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Therapeutic angiogenesis using genetically engineered human endothelial cells.

Seung-Woo Cho1, Fan Yang, Sun Mi Son

  • 1Department of Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|March 28, 2012
PubMed
Summary
This summary is machine-generated.

Biodegradable nanoparticles enhance cell therapy for ischemic disease by improving cell survival and engraftment. This gene therapy approach using vascular endothelial growth factor (VEGF) promotes angiogenesis and limb salvage.

More Related Videos

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood

Published on: January 6, 2022

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
07:40

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery

Published on: May 16, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood

Published on: January 6, 2022

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
07:40

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery

Published on: May 16, 2018

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Vascular Biology

Background:

  • Cell therapy shows potential for treating ischemic diseases.
  • Poor in vivo cell survival limits the efficacy of current cell therapies.
  • Genetic modification can enhance transplanted cell survival and function.

Purpose of the Study:

  • To develop a non-viral gene therapy method to improve endothelial cell survival and engraftment in ischemic tissue.
  • To utilize biodegradable poly(β-amino esters) (PBAE) nanoparticles for delivering vascular endothelial growth factor (VEGF) to human umbilical vein endothelial cells (HUVECs).

Main Methods:

  • Developed biodegradable PBAE nanoparticles for gene delivery.
  • Transfected HUVECs with VEGF using PBAE nanoparticles.
  • Assessed VEGF expression, survival factors, and viability under simulated ischemic conditions.
  • Evaluated HUVEC engraftment, survival, angiogenesis, and limb salvage in a mouse hindlimb ischemia model.

Main Results:

  • PBAE nanoparticle transfection significantly enhanced VEGF expression in HUVECs compared to commercial reagents.
  • Transfection upregulated survival factors and improved HUVEC viability under simulated ischemia.
  • In vivo, VEGF nanoparticle transfection promoted HUVEC engraftment, survival, and angiogenesis, leading to improved ischemic limb salvage.

Conclusions:

  • Biodegradable polymer nanoparticles offer a safe and effective platform for genetic engineering of endothelial cells.
  • This approach enhances therapeutic angiogenesis and improves outcomes in ischemic disease models.
  • Non-viral gene therapy with VEGF-delivering nanoparticles represents a promising strategy to overcome cell therapy limitations.